Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

Haeseong Park · SciRah

Researcher profile · Semantic Scholar

Haeseong Park

Share profile

Haeseong Park — researcher profile on SciRah

h-index: 32
Works: 202
Citations: 6,889

Most-cited papers

Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
J. Ajani, T. D'Amico, D. Bentrem, J. Chao +37 more
2022The Journal of the National Comprehensive Cancer Network1,522 citations Open access
Semantic Scholar
NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY Esophageal and Esophagogastric Junction Cancers, Version 2.2019
J. Ajani, D. ThomasA., Amico, D. Bentrem +33 more
2019642 citations
Semantic Scholar
Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study
S. Modi, Haeseong Park, R. Murthy, H. Iwata +13 more
2020Journal of Clinical Oncology577 citations Open access
Semantic Scholar
Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial
M. Disis, M. Taylor, K. Kelly, J. Beck +13 more
2019JAMA Oncology416 citations Open access
Semantic Scholar
Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors
J. Tsurutani, H. Iwata, I. Krop, P. Jänne +12 more
2020Cancer Discovery292 citations Open access
Semantic Scholar
Durvalumab, tremelimumab alone or in combination with low-dose or hypofractionated targeted radiotherapy in metastatic non-small cell lung cancer refractory to prior PD(L)-1 therapy: a multicentre, open-label, randomised, phase 2 trial
J. Schoenfeld, A. Giobbie-Hurder, S. Ranasinghe, Katrina Z Kao +33 more
2022The Lancet Oncology193 citations Open access
Semantic Scholar
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study.
K. Shitara, H. Iwata, S. Takahashi, K. Tamura +11 more
2019The Lancet Oncology185 citations
Semantic Scholar
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline
M. Shah, E. Kennedy, A. Alarcon-Rozas, T. Alcindor +23 more
2023Journal of Clinical Oncology181 citations Open access
Semantic Scholar
Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial.
D. Catenacci, Yoon-Koo Kang, Haeseong Park, H. Uronis +30 more
2020The Lancet Oncology161 citations
Semantic Scholar
Trastuzumab deruxtecan in Western patients with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen: results from a phase 2, single-arm study
E. Van Cutsem, M. Di Bartolomeo, E. Smyth, I. Chau +12 more
2023The Lancet Oncology128 citations Open access
Semantic Scholar
COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials
A. Desai, J. Gainor, A. Hegde, A. Schram +20 more
2021Nature Reviews Clinical Oncology120 citations Open access
Semantic Scholar
Context-dependent activation of STING-interferon signaling by CD11b agonists enhances anti-tumor immunity
Xiuting Liu, G. Hogg, Chong Zuo, Nicholas C Borcherding +16 more
2023Cancer Cell93 citations Open access
Semantic Scholar
Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers
J. Harding, S. Piha-Paul, Ronak H. Shah, J. Murphy +24 more
2023Nature Communications84 citations Open access
Semantic Scholar
Interferon-induced IDO1 mediates radiation resistance and is a therapeutic target in colorectal cancer
Bao-Sheng Chen, David M. Alvarado, Micah Iticovici, Nathan S. Kau +4 more
2020Cancer immunology research78 citations
Semantic Scholar
Race and ethnicity representation in clinical trials: findings from a literature review of Phase I oncology trials.
D. Camidge, Haeseong Park, K. Smoyer, I. Jacobs +4 more
2021Future Oncology49 citations Open access
Semantic Scholar
First in Human Phase 1/2 ICONIC Trial of the ICOS agonist vopratelimab alone and with nivolumab: ICOS-hi CD4 T cell populations and predictors of response
T. Yap, J. Gainor, M. Callahan, G. Falchook +30 more
2022Clinical Cancer Research46 citations Open access
Semantic Scholar
Tolerability and safety of EUS-injected adenovirus-mediated double-suicide gene therapy with chemotherapy in locally advanced pancreatic cancer: Phase I Trial.
Jongchan Lee, D. Shin, Haeseong Park, Jinkuk Kim +4 more
2020Gastrointestinal Endoscopy46 citations
Semantic Scholar
Gastric Cancer, Version 2.2022
J. Ajani, D. ThomasA., Amico, D. Bentrem +38 more
202243 citations
Semantic Scholar
KRYSTAL-2: A phase I/II trial of adagrasib (MRTX849) in combination with TNO155 in patients with advanced solid tumors with KRAS G12C mutation.
J. Sabari, Haeseong Park, A. Tolcher, S. Ou +11 more
202143 citations
Semantic Scholar
ctDNA MRD Detection and Personalized Oncogenomic Analysis in Oligometastatic Colorectal Cancer From Plasma and Urine
B. Pellini, N. Pejovic, W. Feng, N. Earland +19 more
2021JCO Precision Oncology43 citations Open access
Semantic Scholar
Nonoperative Rectal Cancer Management With Short-Course Radiation Followed by Chemotherapy: A Nonrandomized Control Trial.
Hyun Kim, K. Pedersen, J. Olsen, M. Mutch +17 more
2021Clinical colorectal cancer36 citations
Semantic Scholar
Targeting HER2 (ERBB2) mutation-positive advanced biliary tract cancers with neratinib: Results from the phase II SUMMIT ‘basket’ trial.
J. Harding, J. Cleary, D. Quinn, I. Braña +16 more
202132 citations
Semantic Scholar
First-in-human study of REGN3767 (R3767), a human LAG-3 monoclonal antibody (mAb), ± cemiplimab in patients (pts) with advanced malignancies.
K. Papadopoulos, N. Lakhani, M. Johnson, Haeseong Park +15 more
2019Journal of Clinical Oncology32 citations
Semantic Scholar
Screening of Carbofuran-Degrading Bacteria Chryseobacterium sp. BSC2-3 and Unveiling the Change in Metabolome during Carbofuran Degradation
Haeseong Park, Sun-il Seo, J. Lim, Jaekyeong Song +2 more
2022Metabolites30 citations Open access
Semantic Scholar
Phase Ib Study of Ulixertinib Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma
P. Grierson, B. Tan, K. Pedersen, Haeseong Park +10 more
2022The Oncologist27 citations Open access
Semantic Scholar
Abstract P6-17-02: Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-low expressing breast cancer: Updated results of a large phase 1 study
S. Modi, J. Tsurutani, K. Tamura, Haeseong Park +12 more
2019Poster Session Abstracts21 citations
Semantic Scholar
Safety and unique pharmacokinetic profile of ARX788, a site-specific ADC, in heavily pretreated patients with HER2-overexpresing solid tumors: Results from two phase 1 clinical trials.
S. Hurvitz, Haeseong Park, S. Frentzas, Catherine M. Shannon +16 more
2021Journal of Clinical Oncology20 citations
Semantic Scholar
Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer
A. Tsimberidou, J. Shaw, D. Juric, C. Verschraegen +11 more
2021Journal of Hematology & Oncology20 citations Open access
Semantic Scholar
Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma
F. Janku, Haeseong Park, S. G. Call, K. Madwani +18 more
2020Clinical Cancer Research20 citations Open access
Semantic Scholar
Impact of BMI in Patients With Early Hormone Receptor–Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial
G. Pfeiler, D. Hlauschek, E. Mayer, C. Deutschmann +47 more
2023Journal of Clinical Oncology19 citations
Semantic Scholar
FP14.15 Neratinib-Based Combination Therapy in HER2-Mutant Lung Adenocarcinomas: Findings from two International Phase 2 Studies
Bob T. Li, L. Gandhi, B. Besse, K. Jhaveri +21 more
202119 citations Open access
Semantic Scholar
Production of (-)-α-bisabolol in metabolically engineered Saccharomyces cerevisiae.
Tae Yeob Kim, Haeseong Park, Sun-ki Kim, Soo-Jung Kim +1 more
2021Journal of Biotechnology19 citations
Semantic Scholar
FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers: A Phase 2 Nonrandomized Clinical Trial.
Haeseong Park, Ramon U. Jin, A. Wang-Gillam, R. Suresh +12 more
2020JAMA Oncology18 citations Open access
Semantic Scholar
Direct Biotransformation of Nonanoic Acid and Its Esters to Azelaic Acid by Whole Cell Biocatalyst of Candida tropicalis
Ji-Young Kim, Minsik Jun, Yeong-Je Seong, Haeseong Park +2 more
2019ACS Sustainable Chemistry and Engineering18 citations
Semantic Scholar
A phase II study of everolimus in patients with advanced solid malignancies with TSC1, TSC2, NF1, NF2 or STK11 mutations
S. Devarakonda, B. Pellini, Luke Verghese, Haeseong Park +7 more
2021Journal of Thoracic Disease17 citations Open access
Semantic Scholar
Neratinib plus fulvestrant plus trastzuzumab (N+F+T) for hormone receptor-positive (HR+), HER2-negative, HER2-mutant metastatic breast cancer (MBC): Outcomes and biomarker analysis from the SUMMIT trial.
K. Jhaveri, J. Goldman, S. Hurvitz, A. Guerrero-Zotano +16 more
2022Journal of Clinical Oncology16 citations
Semantic Scholar
Abstract CT145: Olaparib +/- atezolizumab in patients with BRCA-mutated (BRCAmt) locally advanced unresectable or metastatic (advanced) breast cancer: an open-label, multicenter, randomized phase II trial
K. Fanucci, M. Pilat, Derek Shyr, Y. Shyr +22 more
2023Cancer Research15 citations
Semantic Scholar
Manufacturing‐dependent change in biological activity of the TLR4 agonist GSK1795091 and implications for lipid A analog development
N. Steeghs, A. Hansen, G. Hanna, Elena Garralda +12 more
2022Clinical and Translational Science15 citations Open access
Semantic Scholar
A pilot study of paricalcitol plus nanoliposomal irinotecan and 5-FU/LV in advanced pancreatic cancer patients after progression on gemcitabine-based therapy
P. Grierson, R. Suresh, Benjamin R. Tan, K. Pedersen +9 more
2023Clinical Cancer Research14 citations Open access
Semantic Scholar
Complete Remission of Widely Metastatic Human Epidermal Growth Factor Receptor 2–Amplified Pancreatic Adenocarcinoma After Precision Immune and Targeted Therapy With Description of Sequencing and Organoid Correlates
Daniel A. King, A. Smith, G. Pineda, Michitaka Nakano +29 more
2023JCO Precision Oncology14 citations Open access
Semantic Scholar
762 First-in-human phase 1a study of NG-641, a tumour-selective vector expressing a FAP-TAc bispecific antibody and immune enhancer module, in patients with metastatic/advanced epithelial tumours (STAR)
G. Simon, V. Subbiah, L. Rosen, H. Lenz +8 more
2022Regular and Young Investigator Award Abstracts13 citations Open access
Semantic Scholar
Immunity, Immunotherapy, and Rectal Cancer: A Clinical and Translational Science Review
E. Otegbeye, J. Mitchem, Haeseong Park, A. Chaudhuri +3 more
2020Translational Research: The Journal of Laboratory and Clinical Medicine13 citations Open access
Semantic Scholar
Abstract CT118: Phase I study of defactinib combined with pembrolizumab and gemcitabine in patients with advanced cancer: Experiences of pancreatic ductal adenocarcinoma (PDAC) patients
A. Wang-Gillam, R. McWilliams, A. C. Lockhart, B. Tan +9 more
2020Tumor Biology13 citations
Semantic Scholar
A Phase I Trial of Temsirolimus and Erlotinib in Patients with Refractory Solid Tumors
Haeseong Park, Kerry J Williams, N. Trikalinos, Sarah M. Larson +9 more
2020Cancer Chemotherapy and Pharmacology12 citations Open access
Semantic Scholar
Abstract CT009: Phase II trial of perioperative pembrolizumab plus capecitabine and oxaliplatin followed by adjuvant pembrolizumab for resectable gastric and gastroesophageal junction (GC/GEJ) adenocarcinoma
A. Raufi, Shing M. Lee, Michael S May, A. Del Portillo +8 more
2022Cancer Research11 citations
Semantic Scholar
Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumors
N. Bagegni, Haeseong Park, Katlyn Kraft, M. O'Toole +10 more
2022Cancer Chemotherapy and Pharmacology11 citations Open access
Semantic Scholar
First-in-human study of the B7-H4 antibody-drug conjugate (ADC) AZD8205 in patients with advanced/metastatic solid tumors.
F. Meric-Bernstam, D. Oh, Y. Naito, Toshio Shimizu +12 more
2022Journal of Clinical Oncology11 citations
Semantic Scholar
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma.
D. Catenacci, Yoon-Koo Kang, H. Uronis, Keunsung Lee +28 more
2023Oncology10 citations
Semantic Scholar
A randomized phase II study of nab-paclitaxel + durvalumab + neoantigen vaccine versus nab-paclitaxel + durvalumab in metastatic triple-negative breast cancer (mTNBC).
L. Hernandez-Aya, F. Gao, P. Goedegebuure, Cynthia X. Ma +6 more
2019Journal of Clinical Oncology10 citations
Semantic Scholar
Preliminary clinical and biologic results of GB1275, a first-in-class oral CD11b modulator, alone and with pembrolizumab, in advanced solid tumors (KEYNOTE A36).
Haeseong Park, J. Bendell, W. Messersmith, D. Rasco +10 more
20219 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

A. Wang-Gillam×7
Invite
A. Wang-Gillam — researcher profile on SciRah
R. Suresh×7
Invite
R. Suresh — researcher profile on SciRah
K. Pedersen×6
Invite
K. Pedersen — researcher profile on SciRah
P. Enzinger×5
Invite
P. Enzinger — researcher profile on SciRah

×5

Invite

J. Lacy — researcher profile on SciRah

Invite

H. Iwata — researcher profile on SciRah

S. Piha-Paul×5

Invite

S. Piha-Paul — researcher profile on SciRah

Invite

K. Lim — researcher profile on SciRah

Invite

M. Amin — researcher profile on SciRah

N. Trikalinos×5

Invite

N. Trikalinos — researcher profile on SciRah

Invite

J. Ajani — researcher profile on SciRah

Invite

J. Chao — researcher profile on SciRah